|1.||Elford, Howard L: 5 articles (02/2006 - 08/2002)|
|2.||Mayhew, Christopher N: 3 articles (01/2005 - 11/2002)|
|3.||Gallicchio, Vincent S: 3 articles (01/2005 - 11/2002)|
|4.||Elford, H L: 3 articles (11/2000 - 04/2000)|
|5.||Osanai, Yuu: 2 articles (03/2008 - 05/2007)|
|6.||Ishikawa, Masaaki: 2 articles (03/2008 - 05/2007)|
|7.||Kurauchi, Kaori: 2 articles (03/2008 - 05/2007)|
|8.||Ohtake, Takaharu: 2 articles (03/2008 - 05/2007)|
|9.||Kanno, Syu-Ichi: 2 articles (03/2008 - 05/2007)|
|10.||Ujibe, Mayuko: 2 articles (03/2008 - 05/2007)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2000 - "The present study demonstrates the superiority of hydroxyurea at non-cytotoxic doses compared to the other two recent RR inhibitors: gemcitabine and trimidox in radio-sensitising human pancreatic cancer cells. "
01/01/2000 - "The present study was performed to evaluate the efficacy of two potent ribonucleotide reductase (RR) inhibitors: hydroxyurea and trimidox in radio-sensitising Panc-1 human pancreatic cancer cells in an attempt to identify a more effective chemo-radiotherapy regimen with minimal side effects. "
12/15/1994 - "Trimidox inhibited the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 mumol/L. "
12/15/1994 - "Our results suggest that trimidox in combination with tiazofurin might be useful in the treatment of leukemia."
08/01/2002 - "Trimidox (3,4,5-trihydroxybenzamidoxime) was identified as a potent inhibitor of this enzyme and was shown to significantly decrease deoxycytidine triphosphate (dCTP) pools in HL-60 leukemia cells. "
11/17/2000 - "Trimidox (3,4,5-trihydroxybenzohydroxamidoxime), a recently synthesized inhibitor of ribonucleotide reductase (RR), was shown to exert anti-proliferative activities in HL-60 and K562 human leukemia cell lines and to prolong the life span of mice inoculated with L1210 mouse leukemia cells. "
12/15/1994 - "Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells."
06/01/1992 - "Efficacy of a hydroxyl radical scavenger (VF 233) in preventing reperfusion injury in the isolated rabbit heart."
06/01/1992 - "We tested the hypothesis that 3,4,5,-trihydroxybenzamidoxime (VF 233), a demonstrated hydroxyl radical scavenger and an effective Fe3+ chelator, attenuates reperfusion injury and improves isovolumic left ventricular function. "
06/01/1992 - "Rabbits treated with VF 233 had significant improvement in left ventricular function (expressed as percent return of left ventricular peak developed pressure) within 15 minutes of reperfusion (55.0 +/- 3.0 versus 66.2 +/- 4.1; p less than 0.05 by analysis of variance) after global ischemia and remained significantly improved throughout the reperfusion period. "
06/01/1992 - "These results demonstrate that administration of VF 233 significantly improves ventricular function but does not affect adenine nucleotide metabolism after ischemia and reperfusion."
|5.||Murine Acquired Immunodeficiency Syndrome (MAIDS)
11/01/2002 - "We report a comparison of the efficacy and bone marrow toxicity of HU (400 and 200 mg/kg/day) with the novel RR inhibitors and free radical-scavenging compounds didox (DX; 3,4-dihydroxybenzohydroxamic acid; 350 mg/kg/day) and trimidox (TX; 3,4,5-trihydroxybenzamidoxime; 175 mg/kg/day) in the murine AIDS (LPBM5 MuLV) model of retrovirus infection. "
01/01/2005 - "In this report we have compared the antiviral effects of HU and two novel RR inhibitors trimidox (3,4,5-trihydroxybenzamidoxime) and didox (3,4-dihydroxybenzohydroxamic acid) in combination with didanosine (2,3-didoxyinosine; ddI) in the LPBM5 MuLV retrovirus model (murine AIDS). "
11/01/1997 - "We examined a new series of RRIs, 3,4-dihydroxybenzohydroxamic acid (Didox) and 3,4,5-trihydroxybenzohydroxamidoxime (Trimidox) for their ability to alter disease progression in murine acquired immunodeficiency syndrome (MAIDS), both alone and in combination with 2',3'-dideoxyinosine (ddI). "
11/01/2002 - "Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea."
06/01/2004 - "In this study, the novel RR inhibitors didox (DX; 3,4-dihydroxybenzohydroxamic acid), and trimidox (TX; 3,4,5-trihydroxybenzamidoxime) were evaluated along with HU for anti-retroviral efficacy in LPBM5-induced retro-viral disease (MAIDS) both as monotherapeutic regimens and in combination with the guanine containing NRTI abacavir (ABC). "
|1.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|2.||Drug Therapy (Chemotherapy)